US-based healthcare technology company Aclarion has entered a commercial agreement with AdventHealth’s Porter Hospital facility in Denver, Colorado, to introduce its Nociscan technology for chronic low back pain patients.
AdventHealth Porter will be the first facility in Denver to offer this technology, which measures biomarkers to identify the source of pain in these patients.
Aclarion’s Nociscan is a software-as-a-service (SaaS) platform that aids physicians in distinguishing between painful and nonpainful discs in the lumbar spine by quantifying chemical biomarkers associated with disc pain.
The solution uses magnetic resonance spectroscopy, biomarkers, signal processing techniques and augmented intelligence algorithms to optimise clinical treatments for chronic low back pain.
Aclarion CEO Brent Ness said: “In keeping with our strategy to drive Nociscan to standard of care through key opinion leader advocacy, we applaud AdventHealth Porter in bringing Nociscan technology to Denver in support of Dr Frey’s vision to utilise our technology to improve outcomes while lowering costs.
“The support of pioneering leaders like Dr Frey and AdventHealth is exactly the leadership we need to unequivocally demonstrate the superior clinical outcomes for patients that will drive coverage decisions by payers and give all patients access to Nociscan technology.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
When used in conjunction with other diagnostic tools, Nociscan provides physicians with insights into the location of a patient’s low back pain, helping them optimise treatment strategies.
Clinical data suggests that aligning surgical treatment with the disc levels identified as painful by Nociscan improves patient outcomes and reduces costs.
AdventHealth Porter imaging manager Carol Bermingham said: “We are enthusiastic about adding Nociscan to our MRI capability and believe providing personalised biomarker data to treating physicians is yet another investment in our commitment to providing an environment where our doctors can do their very best for their patients.
“Our radiology service line is always striving to stay on the front edge of the technical advancement curve.”